Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy Academic Article Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents
  • Heart Failure
  • Immunologic Factors
  • Inflammation

abstract

  • Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.

publication date

  • March 16, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(02)08026-1

PubMed ID

  • 11918913

Additional Document Info

start page

  • 936

end page

  • 41

volume

  • 359

number

  • 9310